Tumour and patient factors in renal cell carcinoma-towards personalized therapy

Area of Science:

• Oncology
• Genomics
• Cancer Biology

Background:

• Renal cell carcinoma (RCC) is a heterogeneous cancer with limited complete response rates to current targeted therapies.
• Genomic characterization is crucial for advancing novel therapeutic strategies in advanced RCC.
• Significant intratumour and intertumour genetic heterogeneity exists within RCC.

Purpose of the Study:

• To explore the genomic landscape of renal cell carcinoma (RCC).
• To identify key driver genes and altered pathways in RCC.
• To understand the role of tumor microenvironment and patient factors in RCC treatment response.

Main Methods:

• Large-scale genomic studies utilizing multiple 'omics' platforms.
• Analysis of molecular alterations and their correlation with tumor phenotype and clinical outcomes.
• Investigation of intratumour genetic heterogeneity and its impact on therapy.

Main Results:

• Identification of key driver genes and commonly altered pathways in RCC.
• Discovery of molecular signatures linked to tumor behavior and patient prognosis.
• Recognition of the tumor microenvironment as a critical regulator of RCC biology.
• Understanding of patient-specific factors influencing drug response.

Conclusions:

• RCC is a highly diverse malignancy characterized by significant genetic heterogeneity.
• Intratumour heterogeneity presents challenges for personalized RCC therapy.
• The diversity in genomic alterations offers opportunities for targeted pathway inhibition based on individual tumor molecular profiles.
• Harnessing genomic insights and understanding the tumor microenvironment are essential for developing more effective RCC treatments.